Impact of high-throughput screening in biomedical research

被引：886

作者：

Macarron, Ricardo ^{[1
]}

Banks, Martyn N. ^{[2
]}

Bojanic, Dejan ^{[3
]}

Burns, David J. ^{[4
]}

Cirovic, Dragan A. ^{[5
]}

Garyantes, Tina ^{[5
]}

Green, Darren V. S. ^{[6
]}

Hertzberg, Robert P. ^{[7
]}

Janzen, William P. ^{[8
]}

Paslay, Jeff W. ^{[11
]}

Schopfer, Ulrich ^{[9
]}

Sittampalam, G. Sitta ^{[10
]}

机构：

[1] GlaxoSmithKline, Dept Sample Management Technol, Collegeville, PA 19426 USA

[2] Bristol Myers Squibb Co, Dept Appl Biotechnol, Wallingford, CT 06492 USA

[3] Novartis Inst Biomed Res Inc, Lead Finding Platform, Cambridge, MA 02139 USA

[4] Abbott Labs, Early Pain Discovery Team, Abbott Pk, IL 60064 USA

[5] Sanofi Aventis, Dept Lead Generat & Candidate Realizat, Bridgewater, NJ 08807 USA

[6] GlaxoSmithKline, Dept Computat & Struct Chem, Stevenage SG1 2NY, Herts, England

[7] GlaxoSmithKline, Dept Screening & Compound Profiling, Collegeville, PA 19426 USA

[8] Univ N Carolina, Eshelman Sch Pharm, Ctr Integrat Chem Biol & Drug Discovery, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA

[9] Novartis Inst BioMed Res, CH-4056 Basel, Switzerland

[10] Univ Kansas, Ctr Canc, Inst Adv Med Innovat, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA

[11] Pfizer, Res Ctr Emphasis, Dept Screening Sci, New York, NY USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2011年 / 10卷 / 03期

关键词：

DRUG DISCOVERY; MOLECULAR-BIOLOGY; LEAD DISCOVERY; INHIBITOR; COLLECTION; ASSAYS; OPTIMIZATION; TECHNOLOGY; VALIDATION; DESIGN;

D O I：

10.1038/nrd3368

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.

引用

页码：188 / 195

页数：8

共 66 条

[1] Drug repositioning: Identifying and developing new uses for existing drugs [J].

Ashburn, TT ;

Thor, KB .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :673-683

[2] The completed human genome: implications for chemical biology [J].

Austin, CP .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2003, 7 (04) :511-515

[3]

Banks MN, 2006, RSC BIOMOLEC SCI, P315

[4] Hit and lead generation:: Beyond high-throughput screening [J].

Bleicher, KH ;

Böhm, HJ ;

Müller, K ;

Alanine, AI .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) :369-378

[5] Evolution of cell-based reagent provision [J].

Cawkill, Darren ;

Eaglestone, Simon S. .

DRUG DISCOVERY TODAY, 2007, 12 (19-20) :820-825

[6] Process Validation and Screen Reproducibility in High-Throughput Screening [J].

Coma, Isabel ;

Clark, Liz ;

Diez, Emilio ;

Harper, Gavin ;

Herranz, Jesus ;

Hofmann, Glenn ;

Lennon, Mark ;

Richmond, Nicola ;

Valmaseda, Manuel ;

Macarron, Ricardo .

JOURNAL OF BIOMOLECULAR SCREENING, 2009, 14 (01) :66-76

[7] Drug discovery in jeopardy [J].

Cuatrecasas, Pedro .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (11) :2837-2842

[8] 2-aminothiazole as a novel kinase inhibitor template.: Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor [J].

Das, Jagabandhu ;

Chen, Ping ;

Norris, Derek ;

Padmanabha, Ramesh ;

Lin, James ;

Moquin, Robert V. ;

Shen, Zhongqi ;

Cook, Lynda S. ;

Doweyko, Arthur M. ;

Pitt, Sidney ;

Pang, Suhong ;

Shen, Ding Ren ;

Fang, Qiong ;

de Fex, Henry F. ;

McIntyre, Kim W. ;

Shuster, David J. ;

Gillooly, Kathleen M. ;

Behnia, Kamelia ;

Schieven, Gary L. ;

Wityak, John ;

Barrish, Joel C. .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (23) :6819-6832

[9] From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125):: Fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase [J].

De Corte, BL .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :1689-1696

[10] Evaluation of division-arrested cells for cell-based high-throughput screening and profiling [J].

Digan, ME ;

Pou, C ;

Niu, HL ;

Zhang, JH .

JOURNAL OF BIOMOLECULAR SCREENING, 2005, 10 (06) :615-623

← 1 2 3 4 5 6 7 →